Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá D.C., Colombia.
Mol Neurobiol. 2019 Dec;56(12):8157-8167. doi: 10.1007/s12035-019-01663-0. Epub 2019 Jun 13.
Neurologic complications are commonly regarded as irreversible impairments that stem from limited potential of regeneration of the central nervous system (CNS). On the other side, the regenerative potential of stem cells has been evaluated in basic research, as well as in preclinical studies. Mesenchymal stem cells (MSCs) have been regarded as candidate cell sources for therapeutic purposes of various neurological disorders, because of their self-renewal ability, plasticity in differentiation, neurotrophic characteristics, and immunomodulatory properties. Exosomes are extracellular vesicles which can deliver biological information over long distances and thereby influencing normal and abnormal processes in cells and tissues. The therapeutic capacity of exosomes relies on the type of cell, as well as on the physiological condition of a given cell. Therefore, based on tissue type and physiological condition of CNS, exosomes may function as contributors or suppressors of pathological conditions in this tissue. When it comes to the therapeutic viewpoint, the most promising cellular source of exosomes is considered to be MSCs. The aim of this review article is to discuss the current knowledge around the potential of stem cells and MSC-derived exosomes in the treatment of neurodegenerative diseases.
神经并发症通常被认为是不可逆转的损伤,源于中枢神经系统(CNS)再生潜力有限。另一方面,干细胞的再生潜力在基础研究和临床前研究中得到了评估。间充质干细胞(MSCs)因其自我更新能力、分化可塑性、神经营养特性和免疫调节特性,被认为是治疗各种神经疾病的候选细胞来源。外泌体是可以远距离传递生物信息的细胞外囊泡,从而影响细胞和组织的正常和异常过程。外泌体的治疗能力取决于细胞类型以及特定细胞的生理状态。因此,基于 CNS 的组织类型和生理状态,外泌体可能作为该组织中病理状况的促进剂或抑制剂发挥作用。就治疗观点而言,最有前途的外泌体细胞来源被认为是 MSCs。本文旨在讨论干细胞和 MSC 衍生的外泌体在治疗神经退行性疾病方面的潜在作用。
Mol Neurobiol. 2021-7
J Neonatal Perinatal Med. 2020
Pharmacol Res. 2016-11
Stem Cell Res Ther. 2025-7-15
Chem Biomed Imaging. 2025-2-2
Int J Mol Sci. 2025-2-5
Front Aging Neurosci. 2024-12-20
Protein Cell. 2024-8-9
Front Neurol. 2016-9-12
Int J Mol Sci. 2016-1-21
Nat Rev Drug Discov. 2016-1-22
Stem Cells Transl Med. 2015-10